The European Federation for Medicinal Chemistry (EFMC) is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.

Meetings  October 2014 Next

The Nauta Award for Pharmacochemistry

The "Nauta Award for Pharmacochemistry" was established to honour the memory of Prof. Dr. W. Th. Nauta, whose activities have been very important for the advancement of Medicinal Chemistry in general, and the development of international organisational structures for this discipline.

The Nauta Award will acknowledge outstanding results of scientific research in the field of Medicinal Chemistry obtained by scientists without restriction regarding nationality. The award is given biennially and consists of a diploma, € 7.500 and an invitation to present a lecture at an EFMC-ISMC symposium.

Previous recipients were: Prof. Alexander Levitzki in 2012, Prof. Camille George Wermuth in 2010, Prof. Hugo Kubinyi in 2008, Prof. P. Porthogese in 2006, Prof. C.R. Ganellin in 2004, Prof. B. Testa in 2002, Prof. Dr. E. De Clercq in 2000, Prof. Dr. H. Timmerman in 1998, Prof. Dr. P. Krogsgaard-Larsen in 1996, Dr. M. Petitou in 1994 and Dr. A.E. Brändström in 1992.


Laureate 2014

Prof. Paul Leeson
GlaxoSmithKline, United Kingdom


Laureate 2012

Professor Alexander Levitzki
The Hebrew University of Jerusalem, Jerusalem, Israel

By awarding the NAUTA prize, the EFMC acknowledges and recognizes outstanding achievements in the advancement of Medicinal Chemistry and the development of international organizational structures in Medicinal Chemistry.

Prof. Levitzki’s research focuses on cell signaling pathways with a special emphasis on the role of tyrosine kinases. He has pioneered the therapeutic concept that tyrosine kinase function can be selectively modulated by small molecule inhibitors, in face of worldwide skepticism whether sufficient selectivity can be obtained. His research opened new territory leading to a number of novel key therapeutic approaches with significant impact in medicinal chemistry, drug development, and advancement of human health care.

Alexander Levitzki has been the early pioneer in the field of kinase inhibition and antitumor therapy with his work being documented in more than 350 publications. The development and launch of several Protein Tyrosine Kinase inhibition-based cancer therapies highlights the impact Alexander Levitzki’s creative and innovative research has had on medicinal chemistry and industrial R&D with successful drugs already on or coming to the market.

 


Laureate 2010

Prof. Camille George Wermuth, University Louis Pasteur Strasbourg and Prestwick Chemicals, France
Wi
nner of the 2010 Nauta Award for Pharmacochemistry

For his significant contribution to the science of medicinal chemistry, both by scientific achievements and by educational activities. Prof. Wermuth contributed to the development of three marketed drugs and the results of his work are documented in more than 250 publications and 60 patents. He has also significantly contributed to the advancement of education in medicinal chemistry by his famous textbook “The Practice of Medicinal Chemistry”. This award also recognises the engagement of Prof. Wermuth in promoting Medicinal Chemistry in Europe by organizing several symposia and through his active role in learned societies.


Laureate 2008

Prof. Hugo Kubinyi, BASF SE and University of Heidelberg, Germany
Winner of the 2008 Nauta Award for Pharmacochemistry

This award recognises Professor Kubinyi’s contributions in the development, application and dissemination of the rational drug discovery in medicinal chemistry. The results achieved by Prof. Kubinyi are documented in more then 100 publications and seven books that have been particularly instrumental in providing excellent handbooks for newcomers and experienced practitioners to the fields of medicinal chemistry. The development and launch into the market of Meproscillarin (CLIFT), a partially synthetic cardiac glycoside, provides a powerful example of the success achieved by Prof. Kubinyi as medicinal chemist.


Laureate 2006

Prof. Philip Portoghese, Department of Medicinal Chemistry, University of Minnesota, USA
Winner of the 2006 Nauta Award for Pharmacochemistry

Professor Portoghese receives this award for his many contributions to the field of GPCR science which have led to greater understanding of the way in which these receptors function. He is also recognised for his huge contribution to the scientific community as editor-in-chief of The Journal of Medicinal Chemistry.


Laureate 2004

The Nauta Award 2004 for Prof. C. Robin Ganellin, University College London,

On the basis of his impressive career in both industry, academia and scientific organisations, as well as for his efforts to internationally promote Medicinal Chemistry as a chemical discipline. His key contribution to the discovery of histamine antagonists as a novel class of antiulcer drugs with a major impact to health, was highly appreciated.


Laureate 2002

The Nauta Award 2002 for Bernard Testa (Université de lausanne, Switzerland)

The prize was given for the numerous and excellent contributions of the winner to the advancement of pharmaceutical sciences and medicinal chemistry in particular, both as teacher and as researcher. The jury especially mentioned his achievements in understanding the role of physiochemical properties in drug activity, more precisely in the disposition of medicines. Prof.Testa received his prize at the ISMC in Barcelona, Spain, September 2002.


M T W T F S S
29 30 01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 01 02
All events   |  Future events

Job portal

There are currently no jobs available

Job portal page

Follow us on Twitter

Follow us on LinkedIn

ChemBridgeBoehringer IngelheimNovartisProf Dr W. Th. Nauta FoundationPfizerServierRoche
 Prous Institute for Biomedical ResearchUCBJanssen R&DBentham ScienceBayerMerck